Myasthenia Gravis

Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.

It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.

Clinical trials ongoing at the Institute:

• UCB MG0003 : A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis
• UCB MG0004 : A randomized, open-label extension study to investigate the long-term safety, tolerability of rozanolixizumab in adult patients with generalized myasthenia gravis
• UCB MG0007 : A Phase 3, open-label extension (OLE) study to evaluate 6-week treatment cycles of rozanolixizumab in study participants with gMG
• R3918-MG-2018 : Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
• WN42636/ Luminesce : A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of satralizumab in adult patients with generalized myasthenia gravis
• MOM-M281-011 : Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis